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Introduction: Classic bone tissue engineering involves use of osteogenic cells, growth factors, and bone scaffolds to generate a graft material to 
replace the gold standard which is autogenous bone graft. Several modifications have been applied to the classic approach but none of them can 
fully regenerate bone defects. The current study reviewes the literatures in applications of bone tissue engineering both in vivo and in vitro. Materials 
and Methods: An electronic search in MEDLINE was conducted and both in vivo and in vitro studies were included using bone scaffolds with or 
without osteogenic growth factors or stem cells. In vitro studies which did not investigate cell-scaffold interactions and in vivo studies which did not 
measure new bone formation were excluded. Results: Of 86 studies, 38 concerned in vitro and 48 in vivo studies. These studies were divided into 
six groups based on scaffold which they used: Synthetic, natural, polymers (non-ceramics), composites (polymer+ceramic), metal-based and nano-
scaffolds. The results of the studies were compared in a qualitative manner. In vitro studies were mostly conducted on polymers, while relatively 
more animal and clinical studies were performed on ceramics. The most commonly used scaffolds, stem cells and growth factor were synthetic 
ceramics, bone marrow stem cells and bone morphgenic protein 2, respectively. Conclusion: Determination of the most successful approach was 
not possible due to the presence of several variable and variances in analyzing methods and data report. However, studies which used all three 
components of BTE, including scaffolds, growth factors and stem cells, showed good results both in vitro and in vivo. 
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Introduction 
Tissue engineering is a biological cell-based treatment approach 
and classically involves regenerative cells, inducing factors and 
scaffolds. It is a relatively new therapy developed to overcome 
conventional reparative treatments. In tissue engineering, the 
graft material would be generated outside the body and the 
limitations of autografts as well as donor site complications would 
be eliminated (1, 2). 
In orthopedics and craniomaxillofacial surgeries, tissue 
engineering has been applied to reconstruct bone structures and 
repair bone defects. In bone tissue engineering (BTE) or bone 
engineering, osteogenesis is initiated by osteoblasts, which are 
mostly differentiated forms of stem cells provided by graft 
material (3). After the initiation of osteogenesis, local and 
distant stem cells and also osteoblasts would be attracted to the 
field and participate in bone regeneration. The application of 
different types of cells, such as embryonic stem cells, fetal cells, 
placenta and amniotic fluid cells, umbilical cord cells, bone 
marrow haematopoietic stem cells, mesenchymal stem cells, 
adipose tissue- derived cells and dental-derived tissue stem cells 
have been investigated for bone tissue engineering (4-7). 
However, Bone marrow stem cells (BMSCs) have been used 
more frequently (8). 
The presence of growth factors such as bone morphogenetic 
proteins (BMPs) help to differentiate local or grafted stem cells 
and they can increase the rate of bone regeneration (9). BTE 
usually needs growth factors and cytokines to repeat the natural 
process of bone formation which includes cell colonization, 
proliferation, differentiation and extracellular matrix (ECM) 
deposition (10, 11). Several factors exist in natural bone healing 
and remodeling process. However, providing all these factors for 
tissue engineering seems neither possible nor necessary. It has 
been demonstrated that some of the most important factors such 
as BMP2 could facilitate the bone regeneration process (10). 
BMPs can regulate many steps in bone morphogenesis (12). 
Scaffolds used in bone engineering have an extensive variety. 
The primary goal of using scaffolds is to transfer stem cells and 
growth factors to the site of defects (13, 14). This regeneration is 
influenced by its physical and chemical properties (15, 16). In 
addition, they assist proliferation, differentiation and biosynthesis 
of cells similar to the natural extracellular matrix (17). An ideal  
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Table 1. In vitro studies using synthetic ceramic scaffolds 





Chai et al.(18) CaP-based carriers hPDSCs - 
-Upregulation of OCN, OPN, BMP2, and Runx2 gene 
expression of hPDSCs treated with Ca2+ or Pi. 
-At 14 days, mineralization was observed in osteogenic 
medium 
-At 21 days, Calcium mineral deposition after cell treatment 
with Ca2+, Pi, and combined CaP. 









-Formation of a dense network of multilayered polygonal-
shaped cells with processes allowing cell–cell 
communication on DBX® after 3 weeks. 
- 10 ng/ml OCN  
-The ALP staining of these cells showed intensive staining 
(about 37%).  
-COLA1 was present in about 3% of the cells.   
-On HA, the cells showed no tendency to proliferate or 
migrate. 
Zhao et al. (20) 
CaP constructs 
(reinforced with 
chitosan and fibers) 
hUCMSCs - 
-Successful synthesis of bone minerals.  
-The percentage of mineral area: about 3% at day-7, to 12% 
at day-21. -ALP and OC on the CPC-fiber scaffold was 2-
fold those on CPC control without fibers. 
-This scaffold had mechanical strength matching that of 
cancellous bone. 
Xu et al. (21) 
CPC scaffolds (consisted 
of TCP* and dicalcium 
phosphate-anhydrous 




-Stem-cell-encapsulating CPC construct with chitosan and 
fiber reinforcement reached the strength of cancellous 
bone, which was much stronger than injectable carriers for 
cell delivery including CaP and Bioglass. 
- hUCMSCs synthesized nearly three-fold more bone 
minerals than the hBMSCs in vitro.  




-A 10–14-fold increase of cell number after 2 weeks.  
-The specific ALP activity significant rise from day 1 to day 
7. 
Cai et al. (23) 









-Formation of apatite agglomerates   
-Ca/P molar ratio is 1.42.  
-Better adhesion and proliferation of cells on porous β-
TCP/BG scaffolds than porous β-TCP scaffolds. 





-Osteoblasts adhered and spread on both samples after 7 
days  
-Higher cell proliferation on β-TCMP compared to β-TCP.  




scaffolds (mixture of type 
I and III collagens) 
3.CaP scaffolds 




-Denser colonization of JPC-seeded OPLA scaffolds and 
formation of bone nodules after initiation of osteogenesis.  
- JPCs growing within OPLA scaffolds are able to form CaP 
particles.  
Wagner et al. (26) 
1. Native and plasma-
coated PLGA-scaffolds) 
2.agarmatrix 
with HA (coated with 
0.4% hyaluronic acid 
and native) 
3.Tissue Foil E, as 






For human cells: TissueFoil E > plasma-coated PLGA-
scaffolds > uncoated PLGA-scaffolds. 
For ovine cells: plasma-coated PLGA-scaffolds> Tissue Foil 
E > uncoated PLGA-scaffolds.  
-Average amount of OCN:  9.6 ng/mL for ovine cells and 
7.4 ng/mL for human cells. 










-Production of multiple vital and functioning tissue-
engineered bone pieces of 1.0 ×0.75 cm size within 10 days 
in vitro.  
-Gene expression significantly higher when demineralized 
bone used as biomatrix. 
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Wang et al. (28) β-TCP BMSCs BM Dog #8 
10 mm diameter 
Medial orbital 
wall 
New bone formation after 24 weeks: 62.57 
± 7.40% 
Agacayak et al. 
(29) 
HA/TCP BMSCs PRP Rat #90 
7mm diameter 
Parietal bone 
After 2 weeks bone healing was 14.3% and 
12 weeks bone healing was 85.7% 
Vahabi et al. 
(30) 
HA/TCP BMSCs - Dog #5 
10 * 10 * 10 mm 
mandible body 
New bone formation after 6 weeks were 
46.38% 





Rabbit #15 Muscle pouches 
New bone formation 
12th week: 9.33% 
(control): 7.68% 
Mankani M.H. 


















-Lamellar spacing within scaffolds 
regulates the extent of bone formation: 
 500 ϻm: the most new bone, 200 ϻm: the 
strongest transplants. 
Behnia et al.  
(33) 
HA/TCP BMSCs PDGF Human #4 
Anterior 
maxillary cleft 
After 3 months new bone formation was 
51.3% 









 Rabbit #32 
Ulnar 1.5 cm 
defect 
-New bone formation at 12th week: 
A:5.42±0.43% 
B: 17.12±0.97% 
-New bone formation at 16th week: 
A:7.68+-0.84% 
B: 23.31+-1.41% 
Shayesteh et al. 
(35) 
HA/TCP BMSCs - Human #7 
Maxillary Sinus 
Floor 
After 3 months 41.34% new bone 
formation 
Jafarian et al. 
2008 (36) 
HA/TCP BMSCs - Dog #4 
-10mm TAT  
Mandible 
-Masseter Muscle 
After 6 weeks 29.12% new bone formation 
Eslami et al. 
(37) 
HA/TCP BMSCs - Dog #4 Masseter Muscle 
New bone formation after 2 months was 
29.12% 











-Lesser cell numbers, greater ALP activity, 
more osteogenic potential  
osteocalcin synthesis compared to control 
(no rhBMP 2) 
 




BMSCs PRP Rat #15 
5mm diameter 
parietal bone 











hBMSCs FGF Human 
Case 1. Proximal 
tibia:  4 cm × 3 
cm 
Case 2. Proximal 
ulna: 4 cm ×1 cm  
Case 3. distal 
humerus: 7 cm × 
2.5 cm  
Case 4. Distal 
ulna: 6 cm × 1 cm 
-Complete fusion between the implant 
and the host bone observed 5 to 7 months 
after surgery.  
-No late fractures in the implant zone 
were observed.  









-Giant cells appeared on the fg-HAp at 2 
weeks.  
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-Body fluid permeation was found inside 
the fg-HAp, and the fluid component was 
immunopositive for albumin. Albumin 
was also a main component among 
proteins collected from the in vivo 
implanted fg-HAp. After 4 weeks the 
BMP-2/fg-HAp implant showed 59.0% in 
the total volume of bone and marrow.  

























- Calvarial defects 
: 7.3 mm in 
diameter 
-Calvarial defects: 
8mm in diameter 
and subcutaneous 
-In Ti-BMP2 implant, trabecular bone 
with hemopoietic bone marrow-like tissue 
was seen at day 20. Denser lamellar bone 
at day 40. 
-In the Ti-TGFβ1 implants, extensive 
trabecular bone and hemopoietic bone 
marrow-like tissue was observed and bone 
fill was 36%. 
-In porous CaP-rhBMP-2 cranial 
implants complete closure of the defect 
was observed after 10 weeks and bone fill 
was 53%. 
- In subcutaneous CaP-rhBMP-2 implants 
bone formation was observed at 10 weeks 
and bone fill was 18%. 
Kroese 





and ACS  







-Bone formation in the rhBMP-2 loaded 
Ca-P cement discs after 10 weeks. 
 -No signs of bone formation in the ACS 
(absorbable collagen sponge).  
-Degradation of the Ca-P cement could 
not be confirmed after 10 weeks.  












8mm in diameter 
-After 2 weeks: complete closure of 
defects in the ACS group; callus-like bone 
formation outside the rhBMP 2 loaded 
CaP cement implants.  
-After 10 weeks: Complete closure of the 
defects in all rhBMP 2 loaded specimens 
and in some unloaded specimens. 
Table 3. In vitro studies using natural ceramic scaffolds 
Study Scaffold Type of Cells Type of Growth Factor Result 










-Formation of a dense network of multilayered 
polygonal-shaped cells with processes allowing cell–
cell communication after 3 weeks. 
- 10 ng/ml OCN  
-The alkaline staining of these cells showed 
intensive staining (about 37%).  
-Type 1 collagen was present in about 3% of the 
cells.   
HA 
-The cells showed no tendency to proliferate or 
migrate. 














-Production of multiple vital and functioning 
tissue-engineered bone pieces of 1.0 ×0.75 cm size 
within 10 days in vitro.  
-Gene expression significantly higher when 
demineralized bone used as biomatrix. 
Table 4. In vivo studies using natural ceramic scaffolds 
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Study Scaffold Type of Cells 







Khojasteh et al. 
(44) 
Allograft BMSCs FG Rabbit #5 Tibia 
After 2 months 
-2.09mm Mean bone volume 
-New bone formation: 28.5 64.5% 




(control: no cell) 
- Rabbit #30 Femoral 1.5 cm 
4th week:2.4±1.1 
8th week: 5.4±1.1 
12th week:14.4±3.1  
(control): 4th week:0.8±0.8,  
8th week: 3.2±1.5,   
12th week:9.2±1.9   
12th week:  3/5 united 
 (control):1/5  united 







No cells - sheep #16 
Tibial defects: 
3cm 
-After 12 weeks: healing of all 
defects according to radiographs. 
Minor biomechanical properties in 
new bone (11% of the torsional 
strength and 19% of the torsional 
stiffness compared to the collateral 
tibiae) 





BMSCs - Human #2 
Unilateral 
Alveolar Cleft 
After 4 months  
-Integrity of nasal floor 
-35.4% the mean postoperative 
defect of patient 1 
25.6% the mean postoperative defect 
of patient 2 




(control: no cell) 
PRP Sheep #10 
3cm wide 
metatarsal bone  
4th month :- :5/6  compelete healing   
(control) :1/4 distal osteotomy --- 
line completely healed but the 
proximal osteotomy line remained 
detectable 
- New bone formation: 
32.3% to 42.8%  
(control) : 6.7% to 10.5% 
Table 5. In vitro studies using polymers and non-ceramic scaffolds 




Tenorio et al. (4) 
hyaluronic acid 
(Mesolis) and collagen 
foams 
(Tissue Fleece). 
Human fetal bone 
cells  - 
-Cell proliferation in both scaffolds at 70% capacity 
compared to monolayer culture.  
-Collagen foam: better structure for cell delivery if 
cavity filling is necessary. 
-Hydrogels:  injectable technique for difficult to treat 
areas. 
 
Naito et al. (49) 





like tissues conditioned 
with osteoinductive 
supplements 
Rat MSCs* - 
-Better osteoblastic differentiation in the hydrogel 
cultures than 2D cultures. 
-Enhanced biomechanical properties in  ring-shaped 
bone-like tissues with osteoinductive supplements 
 
Idris et al. (50) 
Poly (LLA-co-CL)*, 
Poly (LLA-co-DXO)* 
and PLLA * scaffolds. 
(12.5 mm ×1.5 mm) 
 
Human osteoblast-
like cells - 
-After 14 days extensive ECM formation and cell 
growth were seen on test scaffolds. 
-Increased mRNA expression of the ALP, COL 1, 
BSP, OCN, OPN, and Runx2 genes. 





By day 8: 
-static scaffolds cell density was 67% ± 5.0% in 
periphery and 0.3% ± 0.3% in core. 
-Flow-perfused scaffolds cell density was 94% ± 8.3% 
in periphery and 76% ± 3.1% in core.  
-Thick (>6 mm) 3D constructs are sustainable using a 
flow-perfusion bioreactor.  
Ekaputra et al. 
(52) 
PCL  and PCL/Col 
fabricated by pBMMCs - 
-PCL+Col: better attachment, spreading, and 
proliferation of cells. 
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electrospinning 
technique 
-Culturing under dynamic conditions enhanced bone-
like tissue formation and mechanical strength.  
Alexander et al.   
(25) 
1. OPLA*  scaffolds, 
2.collagen composite 
scaffolds (mixture of 
type I and III collagens)  
3.CaP scaffolds 
(5 mm × 4.5 mm) 
human 
JPC BMP 2 
-Denser colonization of JPC-seeded OPLA scaffolds 
and formation of bone nodules after initiation of 
osteogenesis.  
- JPCs growing within OPLA scaffolds are able to 
form CaP particles. 
 
Lode et al. (17) 




(10 mm × 4 mm) 
hBMSCs - 
-Higher cell numbers: better colonization. 
-Lowest cell density: the highest proliferation rate and 
specific ALP activity  
-A saturation phenomenon was observed; On average 
1.7 × 103 cells were attached to the polystyrene surface 
of the seeding wells. 
 






-Mutated cells adhered more to each other than wild-
type. They tended to grow in patches which formed 
bone nodules. 
-Poorer culture growth in syndromic patients.  
Wagner et al. (26) 
1. native and plasma-
coated PLGA-scaffolds) 
2.agarmatrix 
with HA (coated with 
0.4% hyaluronic acid 
and native) 





For human cells: TissueFoil E > plasma-coated 
PLGA-scaffolds > uncoated PLGA-scaffolds. 
For ovine cells: plasma-coated PLGA-scaffolds> 
TissueFoil E > uncoated PLGA-scaffolds.  
-Average amount of osteocalcin:  9.6 ng/mL for ovine 
cells and 7.4 ng/mL for human cells. 
- 59% collagen and 46% alkaline phopsphatase in 
human cells. 





crosslinking at different 
freezing 






-Different freezing temperatures affected the 
architecture of the collagen sponges, but did not affect 
osteoblastic responses to them. 
-Glutaraldehyde crosslinking process resulted in 
higher cell number, might compromise the 
osteoblastic differentiation and mineralization. 
 
Ciapetti et al. (55) PCL  hBMSCs - 
-The use of unfractionated marrow tissue with blood 
can provide a high number of osteogenic precursors. 
 
Eyckmans et al. 
(56) 
in vivo: Collagraft 
carrier 
RPDCs   
HPDCs  
BMP6 
-In vitro, RPDCs expanded than HPDCs. 
-BMP6 stimulated ALP activity but osteogenic 
medium didn’t.  
-In vivo, HPDCs: extensive bone formation; RPDCs: 
no bone formation. 
Weinzlerl et al. 
(57) 
3D osteogenic 
constructs, based on 
collagenous micro-
particles 
Human ATSCs - 
-Calcium deposition in the cell matrix of ATSCs with 
no correlation with the age of the donor.  
-In Two out of three 3D construcs clear zones of 
mineralization (v. Kossa) detected in the area of 
osteocalcin-producing cells. 
Wang et al. (58)  PhosPEG  gMSCs - 
- PhosPEG–PEG cogels: the greatest accumulation of 
calcium after 3 weeks. Mineralization primarily in the 
core of the construct.  
(for cogels in the perimeter of the construct and in 
PEODA gels, homogeneous mineralization). 
Table 6. In vivo studies using polymers and non-ceramic scaffolds 

























8 mm in 
diameter 
-The short-term BMP2/VEGF 
expression by BMSCs: 21% bone 
regeneration at week 12. 
-Bone ingrowth from the edge at 
week 4. 83% bone regeneration at 
week 12. 












defects: 15 mm 
in diameter 
-After 12 days formation of 
multilayered and mineralized 
nodules was observed 
-2 weeks later: high proliferative 
capacity of cells and cluster 
formation. 
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-After 8 weeks: Closure of the 
calvarial defects. 
-After 12 weeks: complete filling of 
the defect with mature bone tissue 
(with the Haversian system) 
Wadagaki et al. 
(61) 
SRBFS* Mouse BMSCs - Mice 
Subcutaneous 
pockets 
-SRBFS promoted osteoblastic 
differentiation of BMSCs in vitro 
and in vivo. 
- Better mineralization in the SRBFS 
group after 12 weeks.  

















5 mm in 
diameter 
-The tissue concentrations of BMP-
2 in animal models:  
Over 100 pg/mg in the HAP-BMP-
FB group and 50 pg/mg in the 
control groups.  
-Enhanced bone formation in the 
HAP-BMP-FB group after 8 weeks.  










- Rats: #12 
Subcutaneous 
pockets 
-Bone formation occured in two 
steps: fibrous bone at day 30 and 
adult-type bone by day 60. 
-Neo-angiogenesis within bone 
nodules.  
-No bone formation in CD34– cells. 








defects: 4 mm 
in diameter 
- flavonols increase osteogenic 
differentiation. Expression of the 
genes were as follows: 
quercetin>kaempferol>chrysin 










(on the back in 
the cervical 
region) 
HPDCs: extensive bone formation; 
RPDCs: no bone formation.  
Ruhe et al. (43)  
1.porous  CaP 
cement and 
ACS 









-After 2 weeks: complete closure of 
defects in the ACS group; callus-like 
bone formation outside the rhBMP-
2 loaded Ca-P cement implants.  
-After 10 weeks: Complete closure 
of the defects in all rhBMP-2 loaded 
specimens and in some unloaded 
specimens. 


















defects: 1.2 cm 
long 
-Significant bone formation 
happened.  
-The mean bone formation index 
(BFI) for the cell-loaded group was 
greater than for the control group at 
all periods especially at 2- and 8-
week radiographs.  
-A trend of resorption adjacent to 
the fixation plate and bony 
deposition on the opposing side was 
detected. This bone started to form 
in the distant area from the 
osteotomy site. 
Redlich et al. (66) PGLA fleeces 
Rabbit 
periosteal cells  
- Rabbits: #5 
Calvaria 
defects: 15 mm 
in diameter 
-In group with cell/fleece 
constructs: intense formation of 
uncalcified bone from both the 
margin and center of the defect. 
Mean defect closure =65% 
-Control groups: marginal bone 
formation. Defect closure=31% 
110                                                                                                                                                                                                     Motamedian et al. 
 
Regeneration, Reconstruction & Restoration 2016;1(3):103-120 
Table 7. In vitro studies using composite scaffolds 
Study Scaffold Type of Cells 
Type of Growth 
Factor 
Result 
Sicchieri et al. 
(11) 
PLGA–CaP scaffolds 
(10mm × 2mm) 
Rat  BMSCs  - 
Statistically significant positive correlation 
between pore size and gene expression (only 
osterix showed a weak correlation) 
Roberts et al. (67) 
5 orthopedic 3D 
matrices composed of 
CaP* particles in an 
open collagen network 
(3mm × 3mm) 
hPDCs - 
hPDCs were differentiated to osteoblasts in 
vitro. 
Reichert et al. 
(68) 
Type I collagen-coated  
circular mPCL–TCP 
scaffolds (5 mm×3 mm) 
Ovine MPCs and 
OBs 
- 
-Proliferation rate in vitro: MPCs>OBs  (after 1, 
3 and 5 days) 
-A plateau phase in both cells (After 6–7 days). 
-Mineralization potential in 3D culture: 
MPCs>OBs (after 4 weeks)  
- cell viability on the scaffolds >90%.  












-Mineralized Col and HA particles detected on 
the surface of the scaffold.  
-The infrared spectra of the Col/HA/PLCL 
scaffold presented significant similarities with 
the FTIR spectra of healthy human bone.  




lactide)- based scaffolds 
with and without 30 wt 






-Static culture (no change in medium): a thick 
collagen rich matrix formation after 3 weeks 
with cells not penetrating deeper than 500 ϻm 
into the scaffolds. 
Bioactive filler enhanced proliferation, early 
osteogenic differentiation, and mineralization. 
-Dynamic cultures: cells present throughout the 
scaffold interior, even in the center.  
Bioactive filler decreased cell numbers and 
inhibited differentiation.  
Santos-Ruiz et al. 
(53)  









-Mutated cells adhered more to each other than 
normal type. They tended to grow in patches 
which formed bone nodules. 
-Poorer culture growth in mutated cells.  
Lechner et al. (71) 
Composite grafts (a 
fibrin–thrombin shell 
and fibrin, thrombin, 








-After 17 days: modification of appearance and 
growth behavior in cells. 
 -In vitro pre differentiated osteoblasts of the 
same clones maintained their osteogenic 
phenotype for more than 28 days in a tissue 
collagen matrix. 






F XIII, TGF-β1, and 
b-FGF 
-Control group: fivefold cell count increase up 
to the 26th day.  
-Addition of 10.0 ng/mL b-FGF: over seven fold 
increase in 33 days.  
-The strongest proliferation in the group with 
0.5 ng/mL TGF-β1 





rat BMSCs - 
Spindle like cells migrating above the 
underlying cell layer after 9 days.  
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Table 8. In vivo studies using composite scaffolds 













After 6 months new bone 
formation was 64% 
Liao et al. (74) PCL/TCP + collagen I pASCs - Mice 
Gluteal 
Muscle Pocket 









After 2 months 48.63% of the 
defect was filled with lamellar 
bone and 24.1% of scaffold was 
remained. 
Sicchieri et al. 
(11) 
PLGA–CaP scaffolds (5mm 
× 2mm) with various pore 
size 
Rat  BMSCs  - Rat # 24 
Calvarial 
defects: 5 mm 
in diameter 
-After 2 weeks: similar amount of 
bone and blood vessels formation 
in all scaffolds; At 4 and 8 weeks 
much more bone formation in 
scaffolds with pores of 470–590 
ϻm.  
-Pore sizes around 1000 ϻm: 
better osteoblast phenotype 
expression,  
-Pore sizes around 500 ϻm: more 
bone formation.  
-In vivo experiment: woven bone 
overlaid by lamellar bone lined by 
bone-lining cells after 8 weeks. 
Roberts et al. 
(67) 
3D matrices composed of 
CaP particles in an open 
collagen network 
hPDCs - Mice Subcutaneous 
-Highest bone and bone marrow 
formation in  NuOss/hPDC 
implant at 13.03%. 
- The bone formed in this 
implant: 65% originating from 
implanted cells.  
-Formation of a cartilage 
intermediate. 
Reichert et al. 
(46) 
Type I collagen-coated 
mPCL–TCP  
ovine MPCs and 
OBs 
- Mice #4 
Subcutaneous 
pockets 
-Osteogenic potential in vivo: 
OBs>MPCs.  
Davies et al. 
(75) 
Composite scaffold from 






- scaffold contributed to bone 
healing in osteotomies 
- Also the application of scaffold 
for socket preservation and sinus 
lift was demonstrated.  







Bone ingrowth occurred in PCL-
TCP scaffold which was 
transplanted with rhBMP-2, and 
MSCs did not affect bone growth 
Lin et al. (14) 
Poly(propylene fumarate)/ 











-New bone localized on the 
scaffold surface, following its 
contours.  
-The total stiffness of the 
constructs was retained for up to 
12 weeks. 
Karp et al. 
(13) 
Filled/-PLGA-CaP 
cylindrical scaffolds (2.4 
mm×2.5 mm) 2. precise 
cylindrically shaped 
scaffolds 





New bone begun to form after 4 
days, and after 7 days bone 
completely invaded the pores of 
scaffolds.  
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Table 9. In vitro studies using metal- based scaffolds 





De peppo et 
al. (77) 
EBM-fabricated cp-
Ti and Ti6Al4V  
porous Scaffolds 
hES-MPs bFGF 
-These scaffolds supported cell attachment and 
growth 
-They did not change the expression of osteogenic 










-Cells proliferate on all materials with a plateau 
phase at day 9.  
-Proliferation rates higher on foams (123 to 163 
percent per day) than on the reference material 
(80% per day).  
-On polished titanium: greater osteocalcin release, 
earlier mineralization of the extracellular matrix.  
-Similar calcium content on all materials at the end. 






















After 5 weeks, histometric analysis 
showed %59.58±7.00 new bone 
formation 










After 24 days, histometric analysis 
revealed 





silica (TiSi 30:70 








-After 1 week: detection of 
multiple patches of unorganized 
mineralizing tissue in all implants.  
-After 12 weeks: new bone 
maturation, mesh fibers 
embedded in lamellar bone.  
-Enhanced distribution of bone in 
the sol-gel coatings 
-bone formation mainly in the 
center of the uncoated scaffolds.  
Table 11. In vitro studies using nano-scaffolds 
Study    Scaffold  Type of Cells 
Type of Growth 
Factor 
Result 










-Formation of a dense network of multilayered polygonal-
shaped cells with processes allowing cell–cell 
communication on DBX® after 3 weeks. 
- 10 ng/ml osteocalcin  
-The alkaline staining of these cells showed intensive 
staining (about 37%).  
-Type 1 collagen was present in about 3% of the cells.   
-On hydroxyapatite, the cells showed no tendency to 
proliferate or migrate. 
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Table 12. In vivo studies using nano-scaffolds 
Study Scaffold 






Implantation Site Result 









8mm in diameter 
Parietal bone 
Bone formation 29.45% after 6 
weeks and 44.55% after 12 weeks 












After 12 weeks 2.52 increase in 
bone height compared to 1.77 in 
control group 








After 4 weeks new bone 
formation was 16.56% with no 
bone union. However after 8 
weeks all samples showed bone 
union 
El-Ghannam 
et al. (85) 
SCPC 
 
No cells rhBMP 2 rabbits 
Segmental ulnar 
defects: 10mm 
- After 4 weeks: defect 
replacement by new bone with 
mature bone characteristics.  
-The SCPC-rhBMP-2 hybrid 
enhanced bone regeneration in 
defect to form a mature bone 
 
scaffold should be biocompatible and reproducible and also easily 
be sterilized (11, 70); rate of scaffold degradation should be the same 
as the rate of regeneration (54); they should have suitable porosity 
to maintain cell attachment and proliferation (54) and mechanical 
stability to resist external forces, cell contraction forces in healing 
process (23, 32, 54). Scaffolds’ mechanical properties are really 
important in load-bearing sites. Their compressive strength should 
be great, but not exceed that of the surrounding bone, because it 
may cause bone resorption (16). 
The aim of the current study was to review the results of 
studies that used the terms tissue engineering or bone engineering 
for describing the nature of their work. 
Materials and Methods 
Study selection 
In vitro and in vivo experiments in the field of BTE were reviewed. 
Studies which used bone scaffolds with or without cells and growth 
factors were included. Only studies which proposed their method 
as BTE or tissue engineering were included. In vivo studies 
including animal, human experiments and case reports were 
excluded. In vitro experiments which did not investigate the 
behavior of cells on the scaffold, including cell attachment, 
proliferation or osteoblastic differentiation, were excluded. In vivo 
studies which did not measure new bone formation were also 
excluded. 
Search Strategy 
Published papers on BTE were found using the following keywords 
alone or ensemble: bone tissue engineering, tissue engineering, 
bone, stem cells, scaffold, growth factor. 
The initial paper selection was done by examining titles and 
abstracts of all selected papers. The full texts of potentially suitable 
articles were obtained for final assessment according to the 
exclusion and inclusion criteria. The reports consist of the most 
relevant data were included and analyzed in a qualitative manner. 
Results 
After data base search 2148 articles were retrieved, finally, 157 of 
them were selected after screening the titles and abstracts. Then 
the full text of these 157 articles was reviewed and finally 86 of 
them were selected based on our data selection criteria (Figure 1). 
These 86 articles include 38 in vitro studies and 48 in vivo studies. 
Included studies were categorized according to the scaffold that 
they used: ceramic, polymer (non-ceramic), composite (ceramic 
+ polymer), nano-scaffolds and metal-based scaffolds. Ceramic 
scaffolds were either natural or synthetic (Figure 2). 
1. Synthetic ceramic scaffolds 
Ceramic scaffolds including hydroxyapatite (HA), tricalcium 
phosphate (TCP), HA-TCP, beta-tricalcium phosphate / bioactive 
glass (β-TCP/BG), β-TCP with Mg (β-TCMP), Calcium 
phosphate cement (CPC) have been used. From the total number 
of ten in vitro studies (Table 1), two of them used BMSCs, and the 
rest of them used cells, such as osteoblast cells, periosteum-
derived cells and umbilical cord mesenchymal stem cells. The 
results were observed one to four weeks after the surgical 
procedure. 
From total number of 17 in vivo studies (Table 2), 13 studies 
used BMSCs, four used no cells, and the rest used multipotent 
adult progenitor cells and pre-osteoblasts. Animal models were 
rats, rabbits and mic. Also, two human studies were reported.  
114                                                                                                                                                                                                     Motamedian et al. 
 
Regeneration, Reconstruction & Restoration 2016;1(3):103-120 
 
Figure1. Study design 
 
Defects were either cranial, calvarial, or subcutaneous. Their 
sizes were at a range of 5 mm to 12 cm. The defect closure was 
observed one to 10 weeks after the surgery. 
2. Natural ceramic scaffolds 
Scaffolds such as human demineralized cancellous bone, human 
autoclaved cancellous bone, demineralized bone matrix (DBX®) 
have been used in seven studies. As demonstrated in Table 3, two 
in vitro studies used human osteoblast cells. 
In five in vivo studies (Table 4), three studies used BMSCs, one 
of them used skeletal stem cells (SSCs), and two others did not use 
any cells. Animal models included rabbit and sheep and one study 
was performed on human. Defect sizes were between 1.5 to 3 cm 
and the results were analyzed after one to four months. 
3. Polymers and non-ceramic scaffolds 
Scaffolds including polycaprolactone (PCL), PCL/collagen 
(PCL/Col), polyurethane, phosphoester-poly (ethylene glycol) 
(PhosPEG), poly (lactic-co-glycolic) acid (PLGA) and open-cell 
poly-L-lactic acid (OPLA) have been used in 24 studies. As shown 
in Table 5, from the total of 14 in vitro studies, 6 of them used 
BMSCs, and the rest of them used cells such as osteoblast cells, 
periosteum-derived cells, human primary osteoprogenitors from 
craniosynostotic patients, human adipose tissue- derived stem 
cells (AdSCs). The results were observed 1 to 3 weeks after. 
From the total number of ten in vivo studies (Table 6), four of 
them used BMSCs, and the rest of them used human AdSCs, 
periosteal- derived cells, pre-osteoblasts. One study did not use 
any types of cells. Animal models were rats, rabbits and mice. 
Defects were cranial, calvarial, femoral, or subcutaneous and their 
sizes were at a range of 4 mm to 1.2 cm. The defect closure was 
observed 12 days to 12 weeks after the surgery. 
4. Composite scaffolds (polymer+ceramic) 
Scaffolds including PCL/TCP, fibrin-alginate-HA, PLGA-CaP, 
PLGA-bioactive glass have also been used. As shown in Table 7, 
from nine in vitro studies, 3 of them used BMSCs, and the rest of 
them used cells such as osteoblast cells or periosteum-derived 
cells. The results were observed 4 days to 8 weeks after. 
Review of in vivo experiments in this category shows that from 
ten studies, four of them used BMSCs (Table 8). The other cell 
types were osteoblasts, gingival fibroblasts, and periosteal cells. 
Animal models were dog, pig, rat and mice. Defects were cranial, 
femoral, or subcutaneous and their sizes were at a range of 2.5 mm 
to 5 mm. The defect closure was observed 4 days to 6 months after 
the surgery. 
5. Metal-based scaffolds 
Scaffolds such as titanium and titanium alloys (Ti6 AL4 V and Ti6 
AL4 V with a CaP coating), titania-silica coated Ti fibers and silver 
have been used in five studies. In two in vitro studies, pre-
osteoblasts, periosteal cells, or human embryonic stem cell-
derived mesodermal Progenitors were mixed with metal scaffolds 
(Table 9).  
In three in vivo study (Table 10), two of them used induced 
pluripotent stem cells (iPSCs) and the other one used BMSCs. 
Animals were mice and rats. Defects were 1.5 to 4 mm and 
histologic evaluations were performed 1 to 12 weeks after surgery. 
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Figure 2. Distribution of studies based on the types of scaffolds 
 
6. Nano-scaffolds 
Nano-scaffolds have been used in recent studies. Nono-sintered, 
nanocrystalline, phase-pure HA and silica -CaP nanocomposite 
are used in the included studies. Only one in vitro study has been 
reported (Table 11). Of the four in vivo studies (Table 12), two 
of them used BMSCs and others either used dental pulp stem 
cells (DPSCs) or no cells.  Animals were rabbits and goats with 
8 mm to 25 mm defects. Animals were sacrificed 4 to 12 weeks 
post-surgery. 
Discussion 
The current review was performed to investigate the current 
trends in the field of BTE. Due to the presence of several 
variables including type of scaffolds, stem cells, growth factors, 
study models and defect sizes (in in vivo studies) as well as 
variability in analyzing methods and data report, 
determination of the most successful approach was not 
possible. However, the results of the studies could be compared 
in a qualitative manner. Most studies in the primary electronic 
search were in vitro studies, only a few of them introduced their 
experiment in vivo. In vitro studies were more focused on 
polymers, while relatively more animal and clinical studies 
were performed on ceramics (Figure 2).  
The term bone engineering classically refers to application of 
stem cells, growth factors and a scaffold for bone regeneration. 
However, the results showed presentation of the tissue 
engineering triangle only in 7 out of 38 in vitro experiments 
(18.4%) and in 16 out of 48 in vivo studies (33.3%). Although, 
due to variability in methods, comparison of the results of these 
studies with those which did not use cells or growth factor was 
not possible, it seems that classic BTE triad would result in better 
stem cells differentiation, proliferation and attachment in vitro 
and proper bone healing in vivo. Combination of HA with 
fibroblast growth factors (FGF) and BMSCs in human with 4-7 
cm tibial and ulnar bone defects resulted in complete fusion 
between the implant and the host bone (40). More than 50% of 
bone formation in maxillary alveolar cleft was reported using 
HA/TCP scaffold loaded with BMSCs and platelet-derived 
growth factor (PDGF) (33). In animal studies application of 
HA/TCP with platelet-rich plasma (PRP) in rats after 2 and 12 
weeks resulted in 14.3% and 85.7% bone healing, respectively. 
Short term bone formation with PLGA discs with BMSCs 
expressing BMP-2 and vascular endothelial growth factors 
(VEGF) was 21% in rabbit (59). 
Ceramic materials, including natural ceramics like 
allografts and synthetic ceramic like β-TCP and HA/TCP are 
the most used scaffold in the reviewed literature. Allografts, as 
an alternative to autogenous bone grafts, primarily show in 
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vivo osteoconductive properties and less commonly 
osteoinductive properties because of the variable attendance of 
growth factors. A combination of allogenic BMSCs in the 
reconstruction of the tibia in sheep showed nearly as much 
bone formation as autogenic BMSCs (86). Human 
demineralized cancellous bone as an allogenic source of bone 
substitute induced more osteoblastic differentiation in vitro 
compared with synthetic bone materials (19). β-TCP is a 
synthetic calcium phosphate, which have good 
biocompatibility and osteoconductivity in both animal 
experiments and clinical settings (87-93). Biphasic ceramics of 
HA/TCP are increasingly being used as a bone substitute in 
orthopedic and maxillofacial regenerative surgeries (94-96). 
According to some investigations, these scaffolds may possess 
osteoinductive property in addition to their osteoconductive 
effects, but these properties are not enough for complete 
regeneration of bone defects, particularly in cases of extensive 
tissue loss (97, 98). One approach used to overcome this 
problem, is to enrich them by osteogenic factors such as stem 
cells, which has been shown to increase the amount of bone 
formation in dogs (36).  
Apart from the variability of scaffolds, other factors may 
also influence treatment outcome in BTE. These factors, 
mainly include the type of cell, the presence and type of growth 
factor, and animal model (for in vivo experiments). Adult stem 
cells (ASCs), the subject of most investigations in bone 
regeneration research, show great promise for using in the oral 
and maxillofacial regions. Undifferentiated cells found in 
almost all specialized tissues. ASCs are able to self-replicate 
and differentiate into various cell types (99, 100). ASCs with 
their potential to bone generating include BMSCs, AdSCs, 
DPSCs, stem cells from human exfoliated deciduous teeth 
(SHED), and periodontal ligament stem cells (PDLSCs) (101). 
In the current review, BMSCs were the most applied stem cell 
in BTE. Successful repair of bone defects with autologous 
BMSCs has been achieved in various animal models (102). The 
application of BMSCs with bone allografts increased bone 
union in rabbits after three months (45). In addition, optimal 
outcome has been achieved using autologous BMSCs to repair 
human bone defects, particularly mandible defects (103-105). 
These studies have shown that BMSCs possessed favorable 
potential for bone regeneration in the oral and maxillofacial 
regions. On the other hand, hUCMSCs synthesized nearly 
three-fold more bone minerals than the hBMSCs in vitro (21). 
Yu et al. (106) demonstrated that bone regeneration with 
DPSCs is comparable with BMSCs. 
Cell proliferation, chemotaxis, differentiation, and matrix 
synthesis could be the results of local delivery of growth 
factors, hence demonstrating possible bone regeneration (107). 
Bone morphogenetic protein-2 (BMP 2) was the most widely 
used growth factor in animal studies. Even if recombinant 
human bone morphogenetic protein 2 (rhBMP2) be used by 
itself, can amplify bone formation, but, its quick spread in the 
implanted spot can reduce its osteoinductive power (76, 108). 
Previous studies have proved that BMP2 can promote 
osteogenic differentiation of ASCs and enhance matrix 
secretion in the process of bone repairs both in vitro and in 
vivo using a scaffold releasing BMP2 (83, 109). The use of 
skeletal stems cells with sheep allograft and PRP compared 
with control group (with no cell and factor), significantly 
increased new bone formation (48). Although addition of PRP 
to β-TCP scaffold seems to increase in vivo bone formation 
(31), BMSCs can induce more bone formation compared with 
PRP (39). 
Different animal models including dog, sheep, goat, pig, 
rabbit, rat and mouse have been used in tissue engineering 
processes. Larger animals like dog, sheep, and pig are known 
as the models with the highest similarity to human (110). 
However, our results show that most of animal models were 
not large. Given the considerable dissimilarities with human 
bone and the small size of the animal, mice and rats are not 
counted as desirable models for bone studies (110). Moreover, 
the type of the defect might also be considered as an 
influencing factor on bone regeneration. There are different 
defect sites with different sizes according to our different 
animal models in studies which were reviewed.  
Future prospects 
Most of the studies in TBE were in vitro trials, but in the last 
15 years, little progress has been made in vivo. Bone 
engineering has not yet achieved a major progress in the clinic. 
In order to provide accurate data in this field, some standards 
need to be defined and used in clinical studies. There are some 
challenges in this field. BMSCs are the most common cells used 
in bone engineering, however, there are some questions of 
whether they lead to the ultimate results or not. Common 
scaffold materials also have some problems, for example, there 
is a risk of inflammation in vivo due to the acidic pH change 
caused by the degradation of biodegradable polymers. The 
rapid prototyping technique has been used to produce specific 
scaffolds with characterized architecture. Ceramics seem to be 
more successful due to osteoconductivity, easy access, and the 
absence of immunological reaction. One method in designing 
scaffolds is the creation of cell environments that resemble 
natural human tissues. New technologies in scaffold 
fabrication such as bioreactors and rapid prototyping may help 
to produce these scaffolds. 
Ex vivo gene therapy is a novel approach in BTE. In this 
method, progenitor cells are transduced by gene therapy to 
express bone forming factors, therefore there is no need for the 
expensive and difficult production of recombinant cells or growth 
factors. This approach has been successful in healing of bone 
defects in animal models. Combination of genetically- modified 
cells with scaffolds has also increased bone formation in vivo. 
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Conclusion 
Among the reviewed studies, the most commonly used scaffold, 
stem cells and growth factor were synthetic ceramics, BMSCs 
and BMP2, respectively. Studies, that used these components 
showed high proliferation, attachment and differentiation of 
cells in vitro and new bone formation in vivo. The presence of 
stem cells and growth factors increased the amount of bone 
formation in vivo. However, some of other studies that did not 
use one of the components of BTE triad also reported relatively 
acceptable results. This shows that modification of scaffolds or 
methodology may facilitate the clinical application of BTE. 
Nano-scaffolds and composite polymer-ceramics have been 
developed more recently and may be alternative to conventional 
scaffolds. Although, bone regeneration using BTE seems to face 
several challenges, new technology in this field may help reach a 
final solution. 
Conflict of Interest: ‘None declared’. 
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